Miscellaneous adverse events with biologic agents (excludes infection and malignancy)

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Anti-tumor necrosis factor-α (anti-TNF) agents are crucial for managing inflammatory bowel disease (IBD).
• Four anti-TNF therapies are FDA-approved for moderate to severe IBD: infliximab, adalimumab, golimumab, and certolizumab pegol.

Purpose of the Study:

• To summarize current knowledge on noninfectious, nonmalignant toxicities associated with anti-TNF agents.
• To inform clinicians about potential adverse events and their management.

Main Methods:

• Literature review of studies on anti-TNF therapies and their adverse events.
• Analysis of reported noninfectious and nonmalignant toxicities.
• Summary of clinical outcomes following cessation of anti-TNF therapy.

Main Results:

• Cessation of anti-TNF therapy typically leads to improvement or resolution of drug-induced complications.
• Understanding these toxicities is key to optimizing patient care and safety.
• Specific noninfectious, nonmalignant adverse events are detailed.

Conclusions:

• Anti-TNF agents are valuable in IBD treatment but require monitoring for adverse events.
• Management strategies, including drug cessation, can effectively mitigate noninfectious toxicities.
• Further research may elucidate mechanisms and refine treatment protocols.